ProQR Therapeutics N.V.
PRQR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PRQR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PRQR
ProQR Therapeutics N.V. is a biopharmaceutical company focused on developing RNA-editing therapies using its Axiomer platform, with lead candidate AX-0810 for cholestatic diseases currently in clinical development.
Key risk: History of losses and uncertain profitability
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2025.
Tracking 1 catalyst for ProQR Therapeutics N.V..
ProQR Therapeutics N.V. is a biopharmaceutical company focused on developing RNA-editing therapies using its Axiomer platform, with lead candidate AX-0810 for cholestatic diseases currently in clinical development.
- ProQR is a biopharmaceutical company with a history of losses and expects to continue incurring significant losses for the foreseeable future [sec · filed 2026-03-12].
- The company's lead program, AX-0810, targets NTCP for cholestatic diseases and is in clinical development [sec · filed 2026-03-12].
- As of 2025-12-31, ProQR reported cash and equivalents of $92.4M, total revenue of $4.7M, net income of -$8.9M, shareholders' equity of $66.7M, and total debt of $30.9M [sec].
- ProQR has a collaboration with Eli Lilly and Company, which may provide milestone and royalty payments [sec · filed 2026-03-12].
- The company's stock price has experienced significant volatility, ranging from $24.99 per share in March 2015 to $0.56 per share in May 2022 [sec · filed 2026-03-12].
What works
- ProQR's Axiomer RNA-editing platform represents a novel technology with potential applications across multiple diseases, including its lead program AX-0810 for cholestatic diseases [sec · filed 2026-03-12].
- The collaboration with Eli Lilly and Company could generate milestone and royalty payments from commercial product sales, if any, providing a potential revenue stream [sec · filed 2026-03-12].
- The company has a cash position of $92.4M as of 2025-12-31, which may support ongoing operations and clinical development for a period [sec].
What to weigh
- ProQR has a history of losses and expects to continue incurring significant losses, with no assurance of achieving or maintaining profitability [sec · filed 2026-03-12].
- The company will require additional capital to fund operations, and failure to obtain financing could prevent completion of development and commercialization of product candidates [sec · filed 2026-03-12].
- Clinical development of drug candidates is lengthy, uncertain, and expensive, and there is no guarantee that ProQR will successfully complete development or obtain regulatory approval for its product candidates [sec · filed 2026-03-12].
- Stockholder activism could divert management attention and resources, and may adversely affect the company's ability to raise capital or pursue strategic transactions [sec · filed 2026-03-12].
From the filings
Quoted directly from source documents.
ProQR has a history of losses and expects to continue incurring significant losses.
“We are a biopharmaceutical company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our ordinary shares.”
SEC filings · March 12, 2026
The company's lead program AX-0810 targets NTCP for cholestatic diseases.
“our lead program AX-0810 for cholestatic diseases targeting NTCP”
SEC filings · March 12, 2026
ProQR will need additional capital to complete development and commercialization.
“We will require additional capital to fund our operations and if we fail to obtain necessary financing, we will not be able to complete the development and commercialization of our product candidates.”
SEC filings · March 12, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · ax-0810 — Phase 2 Readout: ax-0810 — Topline data from the Phase 2 clinical trial of AX-0810 for cholestatic diseases is expected, which will inform the program's advancement.
Risks & what to watch (4)›
Key risks
- History of losses and uncertain profitability — ProQR has a history of losses and expects to continue incurring significant losses, with no guarantee of achieving profitability [sec · filed 2026-03-12].
- Need for additional capital — The company will require additional financing to fund operations and complete development; failure to obtain it could halt progress [sec · filed 2026-03-12].
- Clinical development risks — Drug development is lengthy, uncertain, and expensive; there is no assurance of successful completion or regulatory approval [sec · filed 2026-03-12].
- Stockholder activism — Activist demands could divert management attention and resources, potentially affecting capital raising and strategic initiatives [sec · filed 2026-03-12].
What to watch
- Topline data from the Phase 2 readout of AX-0810, expected by 2026-12-31 [upcoming catalysts].
- ProQR's ability to secure additional financing to support ongoing operations and clinical development [sec · filed 2026-03-12].
- Progress and updates from the collaboration with Eli Lilly and Company, including potential milestone payments [sec · filed 2026-03-12].
- Any developments related to stockholder activism and their impact on the company's strategy and operations [sec · filed 2026-03-12].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run ProQR Therapeutics N.V. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ProQR Therapeutics N.V. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
21.3 months
D/E 1.28
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~123d
5 buys · 0 sells (180d)
Runway
Catalysts
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
64
Total value held
$35.3M
| Holder | Shares | Value |
|---|---|---|
| adage capital partners gp, l.l.c. | 6,253,467 | $10.1M |
| affinity asset advisors, llc | 2,454,278 | $4.0M |
| dafna capital management llc | 1,567,561 | $2.5M |
| morgan stanley | 1,299,775 | $2.1M |
| platinum investment management ltd | 1,235,514 | $2.0M |
| walleye capital llc | 1,215,058 | $2.0M |
| two sigma investments, lp | 918,857 | $1.5M |
| point72 asset management, l.p. | 755,842 | $1.2M |
| citadel advisors llc | 703,323 | $1.1M |
| nomura asset management international inc. | 620,000 | $1.0M |
Showing top 10 of 64 institutional holders of ProQR Therapeutics N.V.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 1.2%
- Days to cover
- 1.0
- Shares short
- 844,972
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PRQR short interestFrequently asked questions
What is the AI investment thesis for ProQR Therapeutics N.V.?
ProQR Therapeutics N.V. is a biopharmaceutical company focused on developing RNA-editing therapies using its Axiomer platform, with lead candidate AX-0810 for cholestatic diseases currently in clinical development.
What is ProQR Therapeutics N.V.'s next catalyst?
ProQR Therapeutics N.V.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: ax-0810" — expected December 31, 2026.
Who is the CEO of ProQR Therapeutics N.V.?
Mr. Daniel Anton de Boer is the chief executive officer of ProQR Therapeutics N.V. (PRQR).
Where is ProQR Therapeutics N.V. headquartered?
ProQR Therapeutics N.V. (PRQR) is headquartered in Leiden, Netherlands.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.